Evidence map›Paper›PMID 37975233›Full record

ArticleOncology reports2024

MicroRNA‑606 inhibits the growth and metastasis of triple‑negative breast cancer by targeting Stanniocalcin 1.

Sujin Choi, Hyun-Ju An, Hyun Jeong Yeo, Min-Ji Sung, Jisu Oh, Kwanbum Lee, Seung Ah Lee, Seung Ki Kim, Junhan Kim, Isaac Kim and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. ElevatedCancer genomics & proteomics · 2025
    Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Sujin Choi *Department of Orthopedic Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi 13488, Republic of Korea.
Hyun-Ju An *Department of Orthopedic Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi 13488, Republic of Korea.
Hyun Jeong YeoDepartment of Orthopedic Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi 13488, Republic of Korea.
Min-Ji SungDepartment of Orthopedic Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi 13488, Republic of Korea.
Jisu OhDivision of Hemato‑Oncology, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Gyeonggi 16995, Republic of Korea.
Kwanbum LeeDepartment of General Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi 13488, Republic of Korea.
Seung Ah LeeDepartment of General Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi 13488, Republic of Korea.
Seung Ki KimDepartment of General Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi 13488, Republic of Korea.
Junhan KimDepartment of Orthopedic Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi 13488, Republic of Korea.
Isaac KimDepartment of General Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi 13488, Republic of Korea.
Soonchul LeeDepartment of Orthopedic Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi 13488, Republic of Korea.
CHA University · KRCHA University Bundang Medical Center · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple‑negative breast cancer (TNBC) is associated with a poor prognosis; however, treatments for TNBC are limited, with poor outcomes. MicroRNAs (miRNAs/miRs) are small non‑coding RNA molecules that are able to regulate gene expression. The present study aimed to identify differentially expressed miRNAs in patients with breast cancer, and to investigate the functional role of the identified miRNA targets and their effects

Indexed as

MicroRNAsTriple Negative Breast NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticGlycoproteinsHumansMiceGlycoproteinsMicroRNAsMIRN606 microRNA, humanteleocalcinmicroRNAmicroRNA‑606Stanniocalcin 1triple‑negative breast cancertumor suppressor

Identifiers

PMID37975233
PMCPMC10688449
OpenAlexW4388716527

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.